MetaVia Inc宣布,其用于治疗肥胖症的药物Da-1726,在1期临床试验的第3部分研究中,已成功完成剂量滴定阶段。这一进展标志着该药物研发过程中的一个重要里程碑。
MetaVia Inc宣布,其用于治疗肥胖症的药物Da-1726,在1期临床试验的第3部分研究中,已成功完成剂量滴定阶段。这一进展标志着该药物研发过程中的一个重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.